PositiveID Corporation - ViaMe

klapdorothypondΚινητά – Ασύρματες Τεχνολογίες

23 Νοε 2013 (πριν από 3 χρόνια και 11 μήνες)

60 εμφανίσεις

February 2012

Forward
-
looking Statements


Information contained in this presentation may contain forward
-
looking statements,
including, but not limited to
:
the expectation that Easy Check and GlucoChip will
eliminate the patient’s need to prick his/her finger multiple
times per day,
the expectation
that
GlucoChip
will have a
one
-
year
life span, that the product launch of
iglucose
is
expected by early 2012, and the development timeline provided for iglucose, Easy Check
and GlucoChip. These forward
-
looking statements are not statements of historical fact
and represent only PositiveID Corporation's beliefs regarding future performance, which
is inherently uncertain. There are a variety of factors, many of which are beyond the
control of PositiveID Corporation, which affect operations, performance, business
strategy and results and could cause actual results and experience to differ materially
from the expectations and objectives expressed in any forward
-
looking statements.
Additional information about these and other factors that could affect PositiveID
Corporation's business is set forth in PositiveID Corporation's various filings with the
Securities and Exchange Commission, including those set forth in PositiveID Corporation's
Form 10
-
K filed on March 25, 2011, and
Forms
10
-
Q filed on May 13,
2011, August 15,
2011, and November 14, 2011, under
the caption “Risk Factors.” PositiveID Corporation
undertakes no obligation to update or release any revisions to these forward
-
looking
statements to reflect events or circumstances after the date of this statement or to
reflect the occurrence of unanticipated events, except as required by law.


2

Key Facts

Symbol

OTCBB: PSID

Corporate Headquarters

Delray Beach, FL

Stock Price (2/1/12) || 52
-
Week Range

$0.14 || $0.12
-
$0.74

Shares Outstanding

80,381,659

Market Cap

$7.9M

Volume (Daily 90
-
Day Average)

271,916

Long
-
Term Debt (9/30/11)

$0.00

Full
-
Time Employees

18

Fiscal Year

December 31

Accounting Firm

EisnerAmper

LLP

3

PositiveID Summary



PositiveID Corporation develops unique medical devices and
molecular diagnostic systems, focused primarily on diabetes
management, rapid medical testing and airborne bio
-
threat
detection products.


It’s key products are:


i
glucose


automatic wireless communication of blood sugar readings


Easy Check


non
-
invasive breath detection of glucose levels


GlucoChip


implantable RFID glucose
-
sensing microchip


M
-
BAND


sample processing and detection of airborne bio
-
threats


Dragonfly


disposable cartridge for biological sample processing and
detection (rapid PCR) for biodefense and clinical applications

4


Easy
-
to
-
use, patent
-
pending wireless device that connects and
communicates automatically from existing data
-
capable glucometers


FDA clearance received November 2011


Collects, records and transmits a patient’s blood glucose data from a
glucometer to the iglucose online database


iglucose correlates data and sends glucose readings via text message, email or fax
to family member, caregiver, physician or other designee


Integrated
iglucometer

with “iglucose inside” prototype complete;
combines FDA
-
cleared glucometer technology with iglucose
communication platform


Global market for glucometers and strips is forecast to reach $18B by
2015*


Three
-
year wireless communication agreement with AT&T


Wireless communication agreement with Rogers Wireless and
CanCare

to
launch in Canada


Commitment to purchase a minimum of 28,000 units


TM

5

*Source: Global Industry Analysts’ “Blood Glucose Meters and Strips: A Global Strategic Business Report,” October 2010

i
glucose Market
Opportunity

Assumptions



Total market size equals 25 million diabetics in the U.S.


End user sale price of $90
device


Monthly subscription of $10 (annualized $120)


Strip sales
-

$0.05 per strip per reading, @ three readings/day

Assumptions


Timeline



510(k) clearance received Nov. 2011


Commercial launch expected in Q1 2012

Total
annual market
size for device sales

Total
annual market
size for
monthly subscription

Total annual
market size for
strip
sales

5% 10%



25
%


50%

Market penetration*


$150


$300


$750


$1,500

5%

10%


25
%


50
%

Market penetration*

5%

10%


25
%


50
%

Market penetration*


$113


$225


$563


$1,125


$68


$137


$342


$684

6

(Device sales and recurring revenue in $ millions on annual basis)


Easy Check™ breath glucose detection device,
under
development, is
a non
-
invasive
glucose detection system that measures acetone levels in a patient’s exhaled
breath


The association between acetone levels in the breath and glucose is well documented


A handheld, battery
-
operated
, portable, easy
-
to
-
use device that includes:


Advanced
laser optical sensor, state
-
of
-
the
-
art microprocessor,
patent
-
pending
chemical sensors


The
goal: patient exhales into the device to test glucose levels without the sample of
blood presently required by existing glucometers


Utilizes single
-
use capsule containing proprietary sodium
nitroprusside
-
based reagent
that triggers a chemical reaction that
is
be measured and correlated to glucose levels


Preliminary lab tests reveal positive results within
industry
standards
for glucometers
as
set by the National Committee of Clinical
Laboratory
Standards (currently Clinical
and Laboratory Standards
Institute


NCCL) and the
International
Organization
for
Standardization
(ISO
)


Could eliminate a patient’s need to prick his/her finger multiple
times a day to get glucose readings


Patent pending


Easy Check Breath Device

7

Easy Check Market Opportunity

Assumptions



Total market size equals 25 million diabetics in the U.S.


End user sale price of $100 device


Replaceable single
-
use cartridge at
$1.00
each


Five
readings/day = over
1,800 readings/year

(Device sales and recurring revenue in $ millions on annual basis)


Timeline



Multi
-
variable/sensitivity testing through 2011


Clinical studies to commence by YE 2011 through 2012


Commercial prototype development in 2012



Annual recurring
revenue @ one
reading/day

Total
annual market
size for device sales

Annual recurring
revenue @ five
readings/day


$125


$250


$625


$1,250

5% 10%


25%


50%

Market penetration*

5%

10
%



25
%



50
%

Market penetration*

5% 10%



25
%



50
%

Market penetration*

*Does not include any assumption of growth in diabetic market.

8


$456


$913


$2,281


$4,563


$2,281


$4,563


$11,406


$22,813

Glucose
-
Sensing Microchip (
GlucoChip
)


From our historical base with the original
VeriChip



the shift from identification to
diagnostic


In vivo

glucose
-
sensing RFID microchip, the GlucoChip™, based on PositiveID’s
Patent No. 7,125,382

for Embedded Bio
-
Sensor System and Receptors’ patented
CARA™ platform


Filed additional utility patent covering the interface between an RF powered resonant
electromechanical drive and the fluids in the interstitial space of a patient for continuous
detection of glucose levels in a patient


GlucoChip will lie completely under the skin to provide continuous glucose sensing;
communicates glucose levels to an external scanner


Phase II development completed


successfully created a stable, reproducible
glucose
-
sensing system and filed related patent


GlucoChip

could negate the need for diabetics to prick their fingers multiple times per
day: the “Holy Grail” of diabetic treatment


According to the American Diabetes Association, 25.8 million people in the U.S., or
8.3% of the population, have diabetes


Annual cost of treating diabetics in U.S. exceeds $110 billion; expected to triple in 25
years, reaching $336 billion*


* According to University of Chicago research published in Diabetes Care, November 2009


9

GlucoChip Design

BIOCOMPATABLE MEMBRANE
BLOODSTREAM GLUCOSE
SIGNAL TRANSDUCTION
AND RFID ELECTRONICS
GLUCOSE BINDING ENVIRONMENT
COMPETITION/SIGNALING COMPONENT
Integrated sensor device design

App
li
ca
tio
n
S
p
e
c
i
f
i
c I
nte
g
r
a
t
ed
Cir
c
uit
(
e
l
ec
tri
ca
l s
e
nso
r
c
i
r
c
uitr
y
)
A
nt
e
nn
a
c
o
il
(
RF
I
D e
na
bl
e
d c
o
mm
uni
ca
ti
o
n)
M
ass

Si
g
na
l
D
e
t
ec
tion
Re
f
e
r
e
nc
e
En
v
ir
o
n
m
en
t
(
No

re
cep
tor
s
)
Co
mpe
titi
o
n /
Si
g
n
a
l
i
ng

Co
mp
on
e
nt
B
io
c
o
mpa
ti
b
l
e m
e
mb
r
a
n
e
B
lo
od
str
e
a
m
Glu
co
se
Glu
co
se
B
in
d
i
n
g

Env
i
ron
me
nt
(
Rec
e
p
t
o
rs in
c
r
y
st
a
l)
G
lucose
S
ensor
C
omp
l
ete As
s
emb
l
y



Mass

D
e
tec
t
ion Type
SENSING
SYSTEM

SENSOR
ELECTRONICS

Components of the sensing/communication device

10

GlucoChip Market Opportunity

Assumptions



Total market size equals 25 million diabetics in
the U.S.


End user sale price of $90 per device


Estimated one
-
year life of device


No sales of scanners or other revenue streams
assumed


(Device sales in $ millions on annual basis)


Timeline



Sensing system completed in Q3 2011


Membrane diffusion and biocompatibility testing
Q4 2011
-
Q1 2012


Sensor optimization and development of MEMS
through mid
-
2012


ASIC development and miniaturization mid
-
2012
-

early 2013


Animal testing and commercial partner Q1 2013



Total market size for device sales


5% 10%


25%


50%


Market penetration*



*Does not include any assumption of growth in diabetic market.

11


$113


$225


$563


$1,125

MicroFluidic Systems


MFS specializes in the development and production of automated systems for a wide
range of applications in the detection and processing of biological samples


Founded in 2001, MFS has received over $45 million in government and commercial

contracts in the last 10 years


Core technologies include sample prep, nucleic acid (DNA and RNA) and protein
detection, automated fluidics and integrated systems


Focused on homeland security and pathogen diagnostic testing (field/clinical/
hospital) opportunities


Strong IP portfolio (29 U.S. Patents and Patents pending) and world
-
class scientific
expertise


Acquired in May 2011; initial consideration of $1.4 million, primarily paid in stock.
Additional earn
-
out of $7.0
million
over four years based
on revenue and earnings
targets

12

M
-
BAND Overview


M
-
BAND Integrated Pathogen Detection Systems


Bio
-
aerosol monitors with fully integrated systems with sample collection, processing
and detection modules. Each module is fully functional and adaptable. MFS has
implemented its own biological assays.


Key technologies:


Multiplexed assays


Networked, remotely operating


Cell
lysis
, nucleic acid purification


Homogeneous,
Taqman

PCR


Monoclonal antibody
-
based toxin detection


Product differentiators:


Rapid confirmation


High sensitivity


Fully autonomous operation


Complete integration of sample collection through toxin and
pathogen detection



13

MFS Market Opportunity

BioWatch



M
-
BAND



Total value of
BioWatch

opportunity is $3.1 billion over approximately five
years


Acquisition of
biodetectors

and replenishment is expected to be 30
-
40% of
total


We are one of only two potentially qualified
biodetector

systems suppliers


Net margins of 15
-
20% expected


Updated RFP expected by Q1 2012


Other opportunities



MFS
has submitted or in
-
process bids totaling $40 million,
some
of which
are expected to be awarded in
early 2012


Opportunities include HHS, DHS, DTRA (Army) and NASA



14

DragonFly

Overview


Dragonfly Integrated Diagnostic Systems


Microfluidic cartridges for biological sample processing and detection including differential
extraction cartridges, sample processing and amplification for biodefense applications, and
clinical sample processing and detection.


Key technologies:


Rapid PCR Amplification


Fluorescent detection


Microfluidic Disposable Cartridges


Automated fluidics


Rapid cell
lysis
, nucleic acid purification


Product differentiators:


Fast results with high integrity


Affordable, disposable, portable


Automated and easy to use


Small operating footprint


Applications:


Environmental bacteria, e.g. E. coli


Clinical samples, e.g. HPV


Antibiotic
-
resistant bacteria, e.g. MRSA


Biothreat

agents


Forensic applications


15

Investment Highlights


Unique, patent
-
pending technologies addressing large markets with
significant unmet needs for new products


Strong management team and outstanding scientists with proven
track records


FDA clearance for iglucose received in November 2011


product
launch expected by early 2012


Easy Check clinical studies commenced in Q4 2011


Significant
BioWatch

opportunity and strong pipeline of $40 million in
potential new government contract opportunities


Initial partnerships in place


16

Balance Sheet

17

(in 000s)
9/30/2011
12/31/2010
Assets
Current assets:
Cash and cash equivalents
472
$

1,764
$

Other current assets
186


1,478


Total current assets
658


3,242


Property and equipment, net
54


49


Goodwill
510


--
Intangibles
1,487


--
Other Assets
258


24


Total assets
2,967
$

3,315
$

Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable
851
$

490
$

Accrued expenses and other current liabilities
1,164


1,219


Total current liabilities
2,015


1,709


Contingent earnout liability
750


--
Stock obligation to related party
3,394


--
Total stockholders’ equity (deficit)
(3,192)


1,606


Total liabilities and stockholders’ equity (deficit)
2,967
$

3,315
$

Cap Structure

18

(Amounts in thousands)
Current
Basic
Full Dil.
Common Shares
Insider & Affiliate
38,068


47.4%
43.0%
Public Float
42,314


52.6%
47.8%
Total Shares
80,382


100.0%
90.8%
Preferred Shares
3,697


4.2%
Stock Options
4,144


4.7%
Warrants
304


0.3%
Total Diluted Shares
8,145


5.0%
Fully Diluted
88,527


100.0%
Ownership %